Biochem J 2000,345(Pt 3):557–564.CrossRefPubMed 28. Wei GX, Campagna AN, Bobek LA: Effect of MUC7 peptides on the growth of bacteria and on

Streptococcus mutans biofilm. J Antimicrob Chemother 2006,57(6):1100–1109.CrossRefPubMed 29. Plummer C, Douglas CW: Relationship between the ability of oral streptococci to interact with platelet glycoprotein Ibalpha and with the salivary low-molecular-weight mucin, MG2. FEMS Immunol Med Microbiol 2006,48(3):390–399.CrossRefPubMed 30. Takamatsu D, Bensing BA, Prakobphol A, Fisher SJ, Sullam PM: Binding of the streptococcal surface glycoproteins GspB and Hsa to human salivary proteins. Infect Immun 2006,74(3):1933–1940.CrossRefPubMed selleck compound 31. Mehrotra R, Thornton DJ, Sheehan JK: Isolation and physical characterization of the MUC7 (MG2) mucin from saliva: evidence for self-association. Biochem J 1998,334(Pt 2):415–422.PubMed 32. Thornton DJ, Devine PL, Hanski C, Howard M, Sheehan JK: Identification of two major populations of mucins in respiratory secretions. Am J Respir Crit Care Med 1994,150(3):823–832.PubMed 33. Kolenbrander PE, Andersen RN: Characterization

of Streptococcus gordonii (S. sanguis) PK488 adhesin-mediated coaggregation with Actinomyces naeslundii PK606. Infect Immun 1990,58(9):3064–3072.PubMed 34. Fontan PA, Pancholi V, Nociari MM, Fischetti VA: Antibodies to streptococcal surface enolase react with human alpha-enolase: implications in poststreptococcal sequelae. J Infect Dis 2000,182(6):1712–1721.CrossRefPubMed 35. Hanski C, Bornhoeft G, Topf N, Hermann U, Stein H, Riecken EO: Detection of a mucin marker for the adenoma-carcinoma Selleckchem HM781-36B sequence inhuman colonic mucosa by monoclonal antibody AM-3. J Clin HMPL-504 cell line Pathol 1990,43(5):379–384.CrossRefPubMed 36. Thornton DJ, Carlstedt I, Howard M, Devine PL, Price MR, Sheehan JK: Respiratory mucins: identification of core

proteins and glycoforms. Biochem J 1996,316(Pt 3):967–975.PubMed 37. Shevchenko A, Wilm M, Vorm O, Mann M: Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996,68(5):850–858.CrossRefPubMed 38. Bergmann S, Rohde M, Chhatwal GS, Hammerschmidt S: alpha-Enolase of Streptococcus pneumoniae is a plasmin(ogen)-binding protein displayed on the bacterial cell surface. Mol Microbiol 2001,40(6):1273–1287.CrossRefPubMed 39. Pancholi V, Fischetti VA: alpha-enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci. Ribociclib in vivo J Biol Chem 1998,273(23):14503–14515.CrossRefPubMed 40. Hughes MJ, Moore JC, Lane JD, Wilson R, Pribul PK, Younes ZN, Dobson RJ, Everest P, Reason AJ, Redfern JM, et al.: Identification of major outer surface proteins of Streptococcus agalactiae. Infect Immun 2002,70(3):1254–1259.CrossRefPubMed 41. Severin A, Nickbarg E, Wooters J, Quazi SA, Matsuka YV, Murphy E, Moutsatsos IK, Zagursky RJ, Olmsted SB: Proteomic analysis and identification of Streptococcus pyogenes surface-associated proteins. J Bacteriol 2007,189(5):1514–1522.CrossRefPubMed 42.

cholerae strains. This procedure could help to determine how relevant the expression of kdpD in V. cholerae is and whether the expression of other genes is reduced or induced in the resistant strains. Conclusions In a high-troughput screening assay with 28,300 compounds the synthetic small molecule vz0825 was identified as the most active antibacterial substance against V. cholerae with an MIC of

1.6 μM and an MBC of 3.2 μM. Whole genome sequencing was carried out with resistant mutants and the two-component Small molecule library screening Histidine kinase KdpD was identified as the prime target of the substance. Further investigations should address the inhibitory mechanism in more detail and corroborate on the possibility of an essential function of KdpD in V. cholerae. Histidine kinase inhibitors are in principal promising antimicrobial drug candidates [30] and compounds like vz0825

Sapanisertib concentration may lead to new treatment options. Methods Strains, media and plasmids The strains used in this study are listed in Table  3. Reporter strain MO10 pG13 was generated from the pathogenic wild type strain MO10, serogroup O139, which was electroporated with the plasmid construct pG13 containing a kanamycin resistance gene (Kmr) and was selected on a plate containing 30 μg/ml Km. V. cholerae strains were grown in LB medium (pH 7.0) at 37°C. LB medium containing Km (30 μg/ml) was used for HTS and Cip (100 μM) was used for positive control. To determine the MIC and MBC values, Mueller-Hinton GNA12 (MH) broth (pH 7.4) was used as growth medium. Susceptibility to ampicillin (Amp), tetracycline Selleckchem S3I-201 (Tet), Cip, rifampicin, chloramphenicol, erythromycin, sulfamethoxazole, and trimethoprim/sulfamethoxazole (SXT) was determined in 96-well MTP containing MH medium supplemented with varied amounts (1 to 1,024 μg/ml) of each antibiotic separately and varied amounts of SXT (0.13/2.38 to 8/152 μg/ml). Supplemented LB medium with Amp (50 μg/ml), Km (30 μg/ml) and Carb (100 μg/ml) was used during the procedures of site-directed mutagenesis and in T medium pH 7.4.

T medium was prepared by adding 17 g tryptone, 3 g neutralized soy peptone, 10 g glucose, 50 mM MOPS, 100 mM NaCl, 2 mM KCl and 2 mM CaCl2 in 1 l of water. For homolog recombination NaCl-free (for increased sucrose sensitivity [31]) LB medium or T medium with 10% sucrose (for induction of pEX18Ap plasmid excision, carrying the sacB gene) was used. Cultivation of the mouse fibroblas cell line L292 was carried out in DMEM with 10% FBS (Lonza). Substance collections Three commercially available substance collections were used in the screening campaigns: i) the LOPAC collection of pharmacologically active compounds with 1,408 entities (Sigma-Aldrich); ii) the Echaz Microcollection with 7,304 compounds (EMC Microcollections GmbH, Tübingen, Germany); and iii) the CDI collection with approximately 17,000 compounds (Chemical Diversity Lab, Inc.